New hope for Hard-to-Treat cancers: NUV-1511 enters human trials
NCT ID NCT06334432
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests a new drug, NUV-1511, in people with advanced solid tumors that have not responded to other treatments. The goal is to find safe doses and see if the drug can shrink tumors in cancers like breast, prostate, pancreatic, and ovarian cancer. About 466 adults will take part in two phases: first to check safety, then to measure effectiveness.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ADVANCED SOLID TUMOR are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Carolina BioOncology Institute
Huntersville, North Carolina, 28078, United States
-
Fred Hutchinson
Seattle, Washington, 98109, United States
-
Hackensack University Medical Center
Hackensack, New Jersey, 07601, United States
-
Karmanos Cancer Center
Detroit, Michigan, 48201, United States
-
Memorial Sloan-Kettering Cancer Center
New York, New York, 10065, United States
-
NEXT Oncology
Irving, Texas, 75038, United States
-
NEXT Oncology
Fairfax, Virginia, 22031, United States
-
START Mountain
Salt Lake City, Utah, 84124, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can pancreatic Cancer's inflammatory footprint be stopped?
- Can your own immune cells beat advanced cancer?
- Could a vaccine help fight Hard-to-Treat cancers?
- Blood and gut clues may flag pancreatic cancer risk early
- A high-tech camera may take the guesswork out of spotting a dangerous surgery complication
- Tumor DNA mapping may unlock personalized cancer therapies